Candidate biomarkers in psychiatric disorders: state of the field
The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …
aid in objectively diagnosing patients and providing individualized treatment …
Glutamatergic dysfunction in Schizophrenia
AO Kruse, JR Bustillo - Translational Psychiatry, 2022 - nature.com
The NMDA-R hypofunction model of schizophrenia started with the clinical observation of
the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or …
the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or …
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …
of patients do not show adequate improvement in positive symptoms with non-clozapine …
Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega …
Importance Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered
brain glutamatergic function may be associated with the pathophysiology of schizophrenia …
brain glutamatergic function may be associated with the pathophysiology of schizophrenia …
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …
Psychotic disorders as a framework for precision psychiatry
F Coutts, N Koutsouleris, P McGuire - Nature Reviews Neurology, 2023 - nature.com
People with psychotic disorders can show marked interindividual variations in the onset of
illness, responses to treatment and relapse, but they receive broadly similar clinical care …
illness, responses to treatment and relapse, but they receive broadly similar clinical care …
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis
Glutamatergic dysfunction is implicated in schizophrenia pathoaetiology, but this may vary in
extent between patients. It is unclear whether inter-individual variability in glutamate is …
extent between patients. It is unclear whether inter-individual variability in glutamate is …
Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment
A de Bartolomeis, G De Simone, M De Prisco… - Molecular …, 2023 - nature.com
Impairment of insulin action and metabolic dysregulation have traditionally been associated
with schizophrenia, although the molecular basis of such association remains still elusive …
with schizophrenia, although the molecular basis of such association remains still elusive …
[HTML][HTML] Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review
Glutamatergic and GABAergic dysfunction are implicated in the pathophysiology of
schizophrenia. Previous work has shown relationships between glutamate, GABA, and brain …
schizophrenia. Previous work has shown relationships between glutamate, GABA, and brain …
Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia
JM Meyer, CU Correll - CNS drugs, 2023 - Springer
Patients with schizophrenia experience a broad range of detrimental health outcomes
resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse …
resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse …